Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
17. Dezember 2024 07:00 ET
|
Immunocore Holdings plc
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First...
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
13. Dezember 2024 08:30 ET
|
Medicenna Therapeutics Corp.
Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive mouse...
FAAM-EUROBAT 2024 Concludes with Groundbreaking Advances in Food Allergy and Anaphylaxis Research
12. Dezember 2024 12:37 ET
|
European Academy of Allergy and Clinical Immunology
ATHENS, Greece, Dec. 12, 2024 (GLOBE NEWSWIRE) -- FAAM-EUROBAT 2024, held from 21-23 November at the InterContinental Athenaeum Athens, brought over 550 attendees from over 25 countries to share...
Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - Valued at $1.16 Billion in 2024, the Industry is Forecast to Generate Revenues of $1.69 Billion by 2028
12. Dezember 2024 05:38 ET
|
Research and Markets
Dublin, Dec. 12, 2024 (GLOBE NEWSWIRE) -- The "Allogeneic T Cell Therapies Market, 2024-2028 & 2033" report has been added to ResearchAndMarkets.com's offering. The allogeneic T cell...
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
11. Dezember 2024 07:00 ET
|
Immunocore Holdings plc
ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to...
Cancer Immunotherapy Strategic Research Business Report 2023-2030: Improved Delivery Systems, Desire for Non-Toxic Treatments, Checkpoint Inhibitors Spur New Developments and Growth
04. Dezember 2024 10:55 ET
|
Research and Markets
Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Cancer...
Wistar Institute Researchers Design Novel Immunotherapy for Brain Cancer
03. Dezember 2024 13:45 ET
|
The Wistar Institute
PHILADELPHIA, PA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- PHILADELPHIA — (December 3, 2024) — The Wistar Institute’s David B. Weiner, Ph.D. — Executive Vice President, director of the Vaccine &...
Nano Drug Delivery System (NDDS) in Cancer Therapy Global Industry Research Report 2024 - Global Forecast to 2030 with Competitive Profiles of 45+ Key Players
03. Dezember 2024 10:04 ET
|
Research and Markets
Dublin, Dec. 03, 2024 (GLOBE NEWSWIRE) -- The "NDDS in Cancer Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for NDDS in...
Sarcoma Drugs Strategic Industry Research Report 2023-2024 & 2030, Competitive Profiles of 42 Players Including Amgen, Bayer, Eisai, Eli Lilly, Johnson and Johnson, Novartis, Pfizer Inc.
03. Dezember 2024 08:48 ET
|
Research and Markets
Dublin, Dec. 03, 2024 (GLOBE NEWSWIRE) -- The "Sarcoma Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Sarcoma Drugs was...
Nouscom Appoints Seasoned Executive Eckhard Niemeier as Chief Business Officer
03. Dezember 2024 03:00 ET
|
Nouscom Srl
BASEL, Switzerland – 3rd December 2024 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies, announces the appointment of...